ADMA ADMA Biologics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ADMA matters now
ADMA Biologics, Inc. (ADMA) is a US stock in Healthcare. The latest InvestLog snapshot shows $9.08 with -2.05% on the session and $2.10B in market capitalization; recent performance reads 1-month -3.71% and YTD -54.44%.
The latest financial table shown here is Q1 2026, with revenue of $114.5M, net income of $45.3M, and EPS of $0.19. Investors can compare that operating picture with valuation signals such as P/E 15.72 and FCF yield 5.6%.
The latest indexable market news headline is "ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $21.00; recent insider activity includes Grossman Jerrold B filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
15.72
PEG
—
P/B
5.03
P/S
3.78
EV/EBITDA
8.99
DCF Value
$-127.61
FCF Yield
5.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
61.3%
Operating Margin
40.6%
Net Margin
32.4%
ROE
39.0%
ROA
24.9%
ROIC
27.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $114.5M | $45.3M | $0.19 |
| Q4 2025 | $139.2M | $49.4M | $0.20 |
| FY 2025 | $510.2M | $146.9M | $0.60 |
| Q3 2025 | $134.2M | $36.4M | $0.15 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$21.00
Target (Median)
$21.00
Target Range
$18.00 - $24.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.73
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.